Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 328 (anti-IL-6 monoclonal antibody) plus mitoxantrone versus mitoxantrone in metastatic hormone-refractory prostate cancer
2006-001671-38Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siltuximab in prostate cancer (PCa) (2 arms), sponsored by Janssen Biotech. Primary endpoints: Safety (Part 1) and Progression-free survival (Part 2). Started Oct 2006; status: completed.
02
Drugs
siltuximab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001671-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001671-38.